Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study. …
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study
March 25, 2024 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
Australia cannot afford complacency on life sciences, AusBiotech warns at 40
October 8, 2026 - - Latest News -
Life sciences sector warns that tax overhaul could push clinical trials offshore
October 8, 2026 - - Latest News -
Moderna and CSIRO launch five year biosecurity collaboration focused on Hendra vaccine
October 8, 2026 - - Latest News